Our findings of the therapeutic effect of tofacitinib were somehow expected and go in line with a recent paper from Lechner et al., which described effectiveness in the treatment of oxazolone induced colitis with downregulation of T cell derived cytokines like IL-5, IL-6, IL-9, IL-13 and IL-17A7. The gene discussed is IL5; the disease is colitis.